			Home About us Contact

Formulation Containing (formulation + containing)

Distribution by Scientific Domains

Medical Sciences	75%

Selected Abstracts

Skin moisturization by hydrogenated polyisobutene,Quantitative and visual evaluation

INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Issue 1 2010
N. Dayan
J. Cosmet. Sci., 60, 15,24 (January/February 2009) Synopsis Hydrogenated polyisobutene (HP) is used in topically applied cosmetic/personal care formulations as an emollient that leaves a pleasing skin feel when applied, and rubbed in after application. This effect, although distinguishable to the user, is difficult to define and quantify. Recognizing that some of the physical properties of HP such as film formation and wear resistance may contribute, in certain mechanisms, to skin moisturization, we designed a short-term pilot study to follow changes in skin moisturization. HP's incorporation into an o/w emulsion at 8% yielded increased viscosity and reduced emulsion droplet size as compared to the emollient ester CCT (capric/caprylic triglyceride) or a control formulation. Quantitative data indicate that application of the o/w emulsion formulation containing either HP or CCT significantly elevated skin moisture content and thus reduced transepidermal water loss (TEWL) by a maximal ,33% against the control formulation within 3 h and maintained this up to 6 h. Visual observation of skin treated with the HP-containing formulation showed fine texture and clear contrast as compared to the control or the CCT formulation, confirming this effect. As a result of increased hydration, skin conductivity, as measured in terms of corneometer values, was also elevated significantly by about tenfold as early as 20 min after HP or CCT application and was maintained throughout the test period. Throughout the test period the HP formulation was 5,10% more effective than the CCT formulation both in reduction of TEWL as well as in increased skin conductivity. Thus, compared to the emollient ester (CCT), HP showed a unique capability for long-lasting effect in retaining moisture and improving skin texture. [source]

Quality of thawed deepwater pink shrimp (Parapenaeus longirostris) treated with melanosis-inhibiting formulations during chilled storage

INTERNATIONAL JOURNAL OF FOOD SCIENCE & TECHNOLOGY, Issue 9 2007
Maria Elvira López-Caballero
Summary This work investigates how the treatment of thawed deepwater pink shrimp (Parapenaeus longirostris) with several melanosis-inhibiting formulations, affects the quality of the shrimp during chilled storage. Formulations were as follows: a formulation containing 4-hexylresorcinol (0.1 and 0.05%), in combination with organic acids and chelating agents, a commercial formula based on sulphites, and a mixture of gluconic acid and commercial sulphites. No noticeable differences were observed for both trimethylamine and total volatile bases during chilled storage. pH evolution was irrespective of the treatment condition. Microbial load enlarged after the sixth day of chilled storage. Higher total bacteria counts were associated with the control and sulphite treatment conditions, while lactic acid bacteria growth seemed to be favoured under formulations based on 4-hexylresorcinol. The appearance of melanosis occurred more rapidly in control shrimp or in shrimp treated with commercial sulphites. 4-hexylresorcinol formulations preserved the quality of thawed shrimp and could replace traditional sulphites. [source]

Circadin: a new option in sleep disorders

PROGRESS IN NEUROLOGY AND PSYCHIATRY, Issue 8 2008
Mark Greener
Circadin - a prolonged-release formulation containing 2mg melatonin - offers a promising short-term treatment for primary insomnia that is characterised by poor sleep quality in patients aged 55 years or over. Medical writer, Mark Greener, reviews this new addition to the sleep treatment armamentarium. Copyright © 2008 Wiley Interface Ltd [source]

Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers

BIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 4 2002
P. Delrat
Abstract A new modified release (MR) formulation containing 30 mg of gliclazide was developed to obtain a better predictable release of the active principle and to allow once-daily dosing regimen. An absolute bioavailability study was carried out to characterise the performance of the new formulation and the food-effect was also investigated in a separate study. Both studies were single dose, randomised, open label, two way cross over studies with a wash out period between doses. For the bioavailability study, each volunteer received 30 mg of gliclazide given either as a 1 h intravenous infusion or as a 30 mg MR tablet. For the food-effect study, the treatment was given either fasted or 10 min after the start of a standardised Melander breakfast. Blood samples were collected up to 72 h after administrations and plasma samples assayed for gliclazide concentrations using a reverse-phase HPLC method with UV detection. Mean absolute bioavailability of gliclazide was 97% and ranged between 79 and 110% showing complete absorption. A similar moderate to low variability was observed after IV and oral administration showing the MR formulation did not add to the overall variability which is solely due to the disposition parameters, in particular metabolism of gliclazide. No significant difference was observed in tmax, t1/2z, Cmax and AUC of gliclazide after administration of the 30 mg MR tablet under fasted and fed conditions. In conclusion, after single oral administration of a 30 mg MR tablet, gliclazide was completely absorbed both under fasted and fed conditions. A consistent and optimal release of gliclazide from this formulation leads to a low to moderate overall variability of its pharmacokinetic parameters. Diamicron 30 mg MR can be given without regards to meals i.e. before, during or after breakfast. Copyright © 2002 John Wiley & Sons, Ltd. [source]